{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:02:30Z","timestamp":1792828950579,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.omtm.2025.101460","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T18:43:42Z","timestamp":1743792222000},"page":"101460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Preclinical studies of an AAV8-CYP4V2 gene therapy VGR-R01 for the treatment of Bietti crystalline dystrophy"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0246-1621","authenticated-orcid":false,"given":"Wenjing","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yezheng","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Shay","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2746-1523","authenticated-orcid":false,"given":"Xi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101460_bib1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/s41433-023-02791-7","article-title":"Longitudinal structure-function analysis of molecularly-confirmed CYP4V2 Bietti Crystalline Dystrophy","volume":"38","author":"Cheloni","year":"2024","journal-title":"Eye"},{"key":"10.1016\/j.omtm.2025.101460_bib2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1086\/383228","article-title":"Bietti Crystalline Corneoretinal Dystrophy Is Caused by Mutations in the Novel Gene CYP4V2","volume":"74","author":"Li","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2025.101460_bib3","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2147\/OPTH.S388292","article-title":"Diagnostic and Management Strategies of Bietti Crystalline Dystrophy: Current Perspectives","volume":"17","author":"Saatci","year":"2023","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.omtm.2025.101460_bib4","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2147\/OPTH.S185744","article-title":"Current perspectives in bietti crystalline dystrophy","volume":"13","author":"Garc\u00eda-Garc\u00eda","year":"2019","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.omtm.2025.101460_bib5","first-page":"654","article-title":"Novel mutations in CYP4V2 in bietti corneoretinal crystalline dystrophy: Next-generation sequencing technology and genotype-phenotype correlations","volume":"25","author":"Meng","year":"2019","journal-title":"Mol. Vis."},{"key":"10.1016\/j.omtm.2025.101460_bib6","first-page":"Doc06","article-title":"Unilateral macular neovascularization formation during the follow-up of a 15-year-old boy with Bietti crystalline dystrophy and the successful treatment outcome with a single intravitreal ranibizumab injection","volume":"13","author":"Kayaba\u015fi","year":"2023","journal-title":"GMS Ophthalmol. Cases"},{"key":"10.1016\/j.omtm.2025.101460_bib7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/mol.112.080085","article-title":"CYP4V2 in Bietti's crystalline dystrophy: ocular localization, metabolism of \u03c9-3-polyunsaturated fatty acids, and functional deficit of the p.H331P variant","volume":"82","author":"Nakano","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.omtm.2025.101460_bib8","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1016\/j.ymthe.2020.07.024","article-title":"PSCs Reveal PUFA-Provoked Mitochondrial Stress as a Central Node Potentiating RPE Degeneration in Bietti\u2019s Crystalline Dystrophy","volume":"28","author":"Zhang","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101460_bib9","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1073\/pnas.1717338115","article-title":"Reduction of lipid accumulation rescues Bietti\u2019s crystalline dystrophy phenotypes","volume":"115","author":"Hata","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2025.101460_bib10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/s41434-020-0159-3","article-title":"Treating Bietti crystalline dystrophy in a high-fat diet-exacerbated murine model using gene therapy","volume":"27","author":"Qu","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2025.101460_bib11","doi-asserted-by":"crossref","first-page":"672449","DOI":"10.3389\/fimmu.2021.672449","article-title":"Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy","volume":"12","author":"Bertolini","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101460_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13287-020-1568-3","article-title":"Rapid generation of purified human RPE from pluripotent stem cells using 2D cultures and lipoprotein uptake-based sorting","volume":"11","author":"Michelet","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.omtm.2025.101460_bib13","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ahg.12388","article-title":"Identification and functional characterization of CYP4V2 genetic variants exhibiting decreased activity of lauric acid metabolism","volume":"84","author":"Jarrar","year":"2020","journal-title":"Ann. Hum. Genet."},{"key":"10.1016\/j.omtm.2025.101460_bib14","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1124\/dmd.109.028530","article-title":"Expression and characterization of CYP4V2 as a fatty acid \u03c9-hydroxylase","volume":"37","author":"Nakano","year":"2009","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.omtm.2025.101460_bib15","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1167\/iovs.13-13717","article-title":"Generation and characterization of a murine model of bietti crystalline dystrophy","volume":"55","author":"Lockhart","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2025.101460_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/13816818309007148","article-title":"Ophthalmic genetics in China","volume":"2","author":"Hu","year":"1983","journal-title":"Ophthalmic. Genet."},{"key":"10.1016\/j.omtm.2025.101460_bib17","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1167\/iovs.17-22473","article-title":"Superior retinal gene transfer and biodistribution profile of subretinal versus intravitreal delivery of AAV8 in nonhuman primates","volume":"58","author":"Seitz","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2025.101460_bib18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.omtm.2021.09.013","article-title":"Biodistribution of intravitreal lenadogene nolparvovec gene therapy in nonhuman primates","volume":"23","author":"Calkins","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101460_bib19","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.ymthe.2023.03.035","article-title":"Ocular stress enhances contralateral transfer of lenadogene nolparvovec gene therapy through astrocyte networks","volume":"31","author":"McGrady","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101460_bib20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.omtm.2017.12.001","article-title":"Nonclinical Safety Evaluation of scAAV8-RLBP1 for Treatment of RLBP1 Retinitis Pigmentosa","volume":"8","author":"MacLachlan","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125000555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125000555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T18:49:55Z","timestamp":1759862995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050125000555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2329050125000555"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101460","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical studies of an AAV8-CYP4V2 gene therapy VGR-R01 for the treatment of Bietti crystalline dystrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Shanghai Vitalgen BioPharma Co Ltd. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101460"}}